High quantum efficiency ruthenium coordination complex photosensitizer for improved radiation-activated Photodynamic Therapy.

PDT - photodynamic therapy PLGA (poly-lactic-co-glycolic acid) radiation radioPDT radiodynamic therapy ruthenium

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 23 06 2023
accepted: 08 08 2023
medline: 13 9 2023
pubmed: 13 9 2023
entrez: 13 9 2023
Statut: epublish

Résumé

Traditional external light-based Photodynamic Therapy (PDT)'s application is limited to the surface and minimal thickness tumors because of the inefficiency of light in penetrating deep-seated tumors. To address this, the emerging field of radiation-activated PDT (radioPDT) uses X-rays to trigger photosensitizer-containing nanoparticles (NPs). A key consideration in radioPDT is the energy transfer efficiency from X-rays to the photosensitizer for ultimately generating the phototoxic reactive oxygen species (ROS). In this study, we developed a new variant of pegylated poly-lactic-co-glycolic (PEG-PLGA) encapsulated nanoscintillators (NSCs) along with a new, highly efficient ruthenium-based photosensitizer (Ru/radioPDT). Characterization of this NP via transmission electron microscopy, dynamic light scattering, UV-Vis spectroscopy, and inductively coupled plasma mass-spectroscopy showed an NP size of 120 nm, polydispersity index (PDI) of less than 0.25, high NSCs loading efficiency over 90% and

Identifiants

pubmed: 37700826
doi: 10.3389/fonc.2023.1244709
pmc: PMC10494715
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1244709

Informations de copyright

Copyright © 2023 Azad, Lilge, Usmani, Lewis, Cole, Cameron, McFarland, Dinakaran and Moore.

Déclaration de conflit d'intérêts

The authors declare the following competing financial interest: SM has a potential research conflict of interest due to a financial interest with Theralase Technologies, Inc. and PhotoDynamic, Inc. A management plan has been created to preserve objectivity in research in accordance with UTA policy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Antioxid Redox Signal. 2014 Jul 20;21(3):396-413
pubmed: 24702237
Nat Rev Clin Oncol. 2015 Sep;12(9):527-40
pubmed: 26122185
Acta Biomater. 2020 Nov;117:335-348
pubmed: 32956872
Nano Lett. 2019 Nov 13;19(11):8234-8244
pubmed: 31576757
Sci Rep. 2020 Dec 17;10(1):22124
pubmed: 33335181
Chem Rev. 2019 Jan 23;119(2):797-828
pubmed: 30295467
CA Cancer J Clin. 2011 Jul-Aug;61(4):250-81
pubmed: 21617154
Theranostics. 2016 Oct 1;6(13):2295-2305
pubmed: 27877235
Sci Rep. 2017 Aug 4;7(1):7315
pubmed: 28779154
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Apoptosis. 2017 Nov;22(11):1321-1335
pubmed: 28936716
Biophys J. 2012 Feb 8;102(3):661-71
pubmed: 22325290
Cancer J. 2013 May-Jun;19(3):200-7
pubmed: 23708066
Nanomedicine (Lond). 2014 Oct;9(15):2339-51
pubmed: 24471504
Front Pharmacol. 2023 Feb 27;14:1137707
pubmed: 36923350
Photochem Photobiol Sci. 2015 Nov;14(11):2014-23
pubmed: 25666432
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Am Chem Soc. 2022 Jun 8;144(22):9543-9547
pubmed: 34882381
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 Jan;15(1):e1838
pubmed: 35959642
Photochem Photobiol Sci. 2018 Nov 1;17(11):1612-1650
pubmed: 29938265
Cell Prolif. 2015 Aug;48(4):465-74
pubmed: 26017818
Front Cell Dev Biol. 2020 Feb 13;8:41
pubmed: 32117972
Photodiagnosis Photodyn Ther. 2013 Dec;10(4):615-25
pubmed: 24284119
Prostate. 2011 Nov;71(15):1668-79
pubmed: 21432867
Cancer Biol Ther. 2013 Jan;14(1):64-74
pubmed: 23114641
Biomed Pharmacother. 2018 Oct;106:1098-1107
pubmed: 30119176
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
J Photochem Photobiol. 2021 Dec;8:
pubmed: 35419549
Mol Oncol. 2020 Jul;14(7):1431-1441
pubmed: 32418368
Adv Drug Deliv Rev. 2003 Sep 26;55(10):1261-77
pubmed: 14499706
Chem Soc Rev. 2021 Mar 21;50(6):4185-4219
pubmed: 33527104
J Photochem Photobiol B. 1990 Jun;6(1-2):143-8
pubmed: 2121931
Pract Radiat Oncol. 2018 Nov - Dec;8(6):354-360
pubmed: 30322661
Neurosurgery. 2019 Jun 1;84(6):E414-E419
pubmed: 30053213
J Neurooncol. 2019 Feb;141(3):477-478
pubmed: 30671710
Theranostics. 2021 Jan 15;11(7):3278-3300
pubmed: 33537087
J Nanosci Nanotechnol. 2006 Apr;6(4):1159-66
pubmed: 16736782

Auteurs

Abul Kalam Azad (AK)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.

Lothar Lilge (L)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Nawaid H Usmani (NH)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.

John D Lewis (JD)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.

Houston D Cole (HD)

Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX, United States.

Colin G Cameron (CG)

Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX, United States.

Sherri A McFarland (SA)

Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX, United States.

Deepak Dinakaran (D)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.
Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD, United States.

Ronald B Moore (RB)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.
Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Classifications MeSH